Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants
© 2023. The Author(s)..
A full understanding of the inactivated COVID-19 vaccine-mediated antibody responses to SARS-CoV-2 circulating variants will inform vaccine effectiveness and vaccination development strategies. Here, we offer insights into the inactivated vaccine-induced antibody responses after prime-boost vaccination at both the polyclonal and monoclonal levels. We characterized the VDJ sequence of 118 monoclonal antibodies (mAbs) and found that 20 neutralizing mAbs showed varied potency and breadth against a range of variants including XBB.1.5, BQ.1.1, and BN.1. Bispecific antibodies (bsAbs) based on nonoverlapping mAbs exhibited enhanced neutralizing potency and breadth against the most antibody-evasive strains, such as XBB.1.5, BQ.1.1, and BN.1. The passive transfer of mAbs or their bsAb effectively protected female hACE2 transgenic mice from challenge with an infectious Delta or Omicron BA.2 variant. The neutralization mechanisms of these antibodies were determined by structural characterization. Overall, a broad spectrum of potent and distinct neutralizing antibodies can be induced in individuals immunized with the SARS-CoV-2 inactivated vaccine BBIBP-CorV, suggesting the application potential of inactivated vaccines and these antibodies for preventing infection by SARS-CoV-2 circulating variants.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Nature communications - 14(2023), 1 vom: 17. Apr., Seite 2179 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Yubin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
Date Completed 19.04.2023 Date Revised 21.04.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-023-37926-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355730987 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355730987 | ||
| 003 | DE-627 | ||
| 005 | 20231226064948.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-023-37926-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1185.xml |
| 035 | |a (DE-627)NLM355730987 | ||
| 035 | |a (NLM)37069158 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Yubin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.04.2023 | ||
| 500 | |a Date Revised 21.04.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a A full understanding of the inactivated COVID-19 vaccine-mediated antibody responses to SARS-CoV-2 circulating variants will inform vaccine effectiveness and vaccination development strategies. Here, we offer insights into the inactivated vaccine-induced antibody responses after prime-boost vaccination at both the polyclonal and monoclonal levels. We characterized the VDJ sequence of 118 monoclonal antibodies (mAbs) and found that 20 neutralizing mAbs showed varied potency and breadth against a range of variants including XBB.1.5, BQ.1.1, and BN.1. Bispecific antibodies (bsAbs) based on nonoverlapping mAbs exhibited enhanced neutralizing potency and breadth against the most antibody-evasive strains, such as XBB.1.5, BQ.1.1, and BN.1. The passive transfer of mAbs or their bsAb effectively protected female hACE2 transgenic mice from challenge with an infectious Delta or Omicron BA.2 variant. The neutralization mechanisms of these antibodies were determined by structural characterization. Overall, a broad spectrum of potent and distinct neutralizing antibodies can be induced in individuals immunized with the SARS-CoV-2 inactivated vaccine BBIBP-CorV, suggesting the application potential of inactivated vaccines and these antibodies for preventing infection by SARS-CoV-2 circulating variants | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a BIBP COVID-19 vaccine |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Vaccines, Inactivated |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Wang, Ziyi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhuang, Xinyu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Shengnan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Zhicheng |e verfasserin |4 aut | |
| 700 | 1 | |a Zou, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Sheng, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Tianpeng |e verfasserin |4 aut | |
| 700 | 1 | |a Tai, Wanbo |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Jinfang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yanqun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Zhaoyong |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yunfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Tong, Liangqin |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Xi |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Linjuan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Dong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Renli |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Ningyi |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Weijun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Jincun |e verfasserin |4 aut | |
| 700 | 1 | |a Tian, Mingyao |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xinquan |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Gong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 14(2023), 1 vom: 17. Apr., Seite 2179 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g number:1 |g day:17 |g month:04 |g pages:2179 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-023-37926-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |e 1 |b 17 |c 04 |h 2179 | ||